Abstract
Omitting cardiovascular diseases, cancer is the first chief death cause globally (Nagai and Kim 2017; Siegel et al. 2020). The term cancer includes over two hundred seventy-seven (277) diseases all specified by uncurbed cell proliferation and this evidence is sufficient for saying that it is not a single disease (Hassanpour and Dehghani 2017). Hippocrates, the father of contemporary medicine was the first physician who used the “carcinos” and “carcinoma” words to describe tumours. The word cancer has been derived from the Greek term “karkinos” or crab. Actually it was Celsus, a Roman physician who translated this Greek word into cancer which is the Latin version for crab (Bynum 2012; Di Lonardo et al. 2015; Grant 2001; Hajdu 2011). Galen, a Greek physician used the term oncos (swelling) in order to describe tumours (Di Lonardo et al. 2015). Majority of cancers form a lump termed as tumour and not all lumps should be considered cancer. While cancerous lumps are known as malignant tumours, the non-cancerous lumps are termed as benign tumours. Certain cancers like leukaemia do not form tumours. Thus all tumours cannot be labelled cancerous, only malignant ones are cancerous. While certain cancers show fast growth and spreading, others show reverse trend. Cancers respond to various treatments differentially.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abbas Z and Rehman S (2018) An overview of Cancer treatment modalities. Neoplasm Book, 1524
Adjei AA (2004) Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 5(Suppl 2):S51–S55
Advani R (2011) Optimal therapy of advanced Hodgkin lymphoma. Hematology 2011:310–316
Apalla Z, Nashan D, Weller RB, Castellsagué X (2017) Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther (Heidelb) 7:5–19
Arner ES (1996) On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Leuk Lymphoma 21:225–231
Avendaño C, Menéndez JC (2008) Chapter 2 - antimetabolites. In: Avendaño C, Menéndez JC (eds) Medicinal chemistry of anticancer drugs. Elsevier, Amsterdam, pp 9–52
Baker WJ, Royer GL Jr, Weiss RB (1991) Cytarabine and neurologic toxicity. J Clin Oncol 9:679–693
Bardal SK, Waechter JE, Martin DS (2011) Chapter 20 - Neoplasia. In: Bardal SK, Waechter JE, Martin DS (eds) Applied pharmacology. Content repository only! Elsevier, Philadelphia, pp 305–324
Baskar R (2010) Emerging role of radiation induced bystander effects: cell communications and carcinogenesis. Genome Integr 1:13
Baskar R, Lee KA, Yeo R, Yeoh K-W (2012) Cancer and radiation therapy: current advances and future directions. Int J Med Sci 9:193–199
Bastide K, Ugolin N, Levalois C, Bernaudin JF, Chevillard S (2010) Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level? Lung Cancer (Amsterdam, Netherlands) 68:1–9
Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444–1454
Begg AC, Stewart FA, Vens C (2011) Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11:239–253
Beutler E (1992) Cladribine (2-chlorodeoxyadenosine). Lancet (London, England) 340:952–956
Bhagavan NV, Ha C-E (2015) Chapter 25 - Nucleotide metabolism. In: Bhagavan NV, Ha C-E (eds) Essentials of medical biochemistry, 2nd edn. Academic Press, San Diego, pp 465–487
Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM (2012) In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer 106:1967–1975
Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6(339–355):363–338
Boulikas T, Pantos A, Bellis E, Christofis P (2007) Designing platinum compounds in cancer: structures and mechanisms. Cancer Ther 5:537–583
Bouquet de Jolinière J, Major A, Khomsi F, Ben Ali N, Guillou L, Feki A (2018) The sentinel lymph node in breast cancer: problems posed by examination during surgery. A review of current literature and management. Front Surg 5:56
Brabec V, Hrabina O, Kasparkova J (2017) Cytotoxic platinum coordination compounds. DNA binding agents. Coord Chem Rev 351:2–31
Buqué A, Muhialdin JS, Muñoz A, Calvo B, Carrera S, Aresti U, Sancho A, Rubio I, López-Vivanco G (2012) Molecular mechanism implicated in pemetrexed-induced apoptosis in human melanoma cells. Mol Cancer 11:25
Bynum WF (2012) Leslie Morton and Robert J Moore, A chronology of medicine and related sciences, Aldershot, Scolar Press, 1997, pp. 784, £75.00 (1-85928-215-6). Med Hist 42:541–542
Canel C, Moraes RM, Dayan FE, Ferreira D (2000) Podophyllotoxin. Phytochemistry 54:115–120
Carver JR (2011) 9 - Management of cardiac and pulmonary treatment–related side effects. In: Davis MP, Feyer PC, Ortner P, Zimmermann C (eds) Supportive oncology. W.B. Saunders, Saint Louis, pp 67–94
Catapano CV, Perrino FW, Fernandes DJ (1993) Primer RNA chain termination induced by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate. A mechanism of DNA synthesis inhibition. J Biol Chem 268:7179–7185
Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76:907–912
Chéreau E, Hudry D, Lambaudie E, Cohen M, Houvenaeghel G, Coutant C (2013) Modèles prédictifs d’envahissement du ganglion non sentinelle en cas de ganglion sentinelle positif dans le cancer du sein. Oncologie 15:304–310
Cheson BD, Vena DA, Foss FM, Sorensen JM (1994) Neurotoxicity of purine analogs: a review. J Clin Oncol 12:2216–2228
Cho R, Cole P, Sohn K-J, Gaisano G, Croxford R, Kamen B, Kim Y-I (2007) Effects of folate and folyipolyglutamyl synthase modulation on chemosensitivity of breast cancer cells. Mol Cancer Ther 6:2909–2920
Chun HG, Leyland-Jones B, Cheson BD (1991) Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 9:175–188
Cohen PA, Jhingran A, Oaknin A, Denny L (2019) Cervical cancer. Lancet (London, England) 393:169–182
Coleman WB (2018) Chapter 4 - Neoplasia. In: Coleman WB, Tsongalis GJ (eds) Molecular pathology, 2nd edn. Academic Press, pp 71–97
Collins CD (2004) Multiple myeloma. Cancer Imaging 4(Spec No A):S47–S53
Colvin ME, Sasaki JC, Tran NL (1999) Chemical factors in the action of phosphoramidic mustard alkylating anticancer drugs: roles for computational chemistry. Curr Pharm Des 5:645–663
Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L (2009) Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag 5:229–238
Corsi A, Calabresi F, Greco C (1978) Comparative effects of cyclophosphamide and isophosphamide on Lewis lung carcinoma. Br J Cancer 38:631–633
Cortes-Funes H, Coronado C (2007) Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 7:56–60
Costa G, Engle RL, Schilling A, Carbone P, Kochwa S, Nachman RL, Glidewell O (1973) Melphalan and prednisone: an effective combination for the treatment of multiple myeloma. Am J Med 54:589–599
Cragg GM, Kingston D, Newman D (2005) Anticancer agents from natural products, pp 1–593
Delaney G, Jacob S, Featherstone C, Barton M (2005) The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104:1129–1137
Desoize B (2004) Metals and metal compounds in cancer treatment. Anticancer Res 24:1529–1544
Devanandan P, Chowdary PR (2013) A review on the use of bleomycin-cisplatin-vinblastine combinations in therapy of testicular cancer. Indian J Res Pharm Biotechnol 1:793–796
Di Lonardo A, Nasi S, Pulciani S (2015) Cancer: we should not forget the past. J Cancer 6:29–39
Di Micco P, Di Micco B (2005) Up-date on solitary plasmacytoma and its main differences with multiple myeloma. Exp Oncol 27:7–12
Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705–713
Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K (1999) Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 10:943–947
Ece B, Eyup B, Aylin Sendemir U (2014) Implementation of nanoparticles in cancer therapy. In: Handbook of research on nanoscience, nanotechnology, and advanced materials. IGI Global, Hershey, pp 447–491
Elson LA (1958) Hematological effects of the alkylating agents. Ann N Y Acad Sci 68:826–833
Emadi A, Jones RJ, Brodsky RA (2009) Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 6:638–647
Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122
Fanale D, Bronte G, Passiglia F, Calò V, Castiglia M, Di Piazza F, Barraco N, Cangemi A, Catarella MT, Insalaco L, Listì A, Maragliano R, Massihnia D, Perez A, Toia F, Cicero G, Bazan V (2015) Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol 2015:690916
Farber S, Diamond LK (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 238:787–793
Feng D, Fidele NB, Agustin MM, Jian G, Bourleyi SI, Augustin L, Olivier NK (2015) Carcinosarcoma of parotid gland (malignant mixed tumor). Ann Maxillofac Surg 5:240–243
Flaherty KT (2006) Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 12:2366s–2370s
Fox EJ (2004) Mechanism of action of mitoxantrone. Neurology 63:S15–S18
Freres P, Jerusalem G, Moonen M (2017) Chapter 2 - Categories of anticancer treatments. In: Lancellotti P, Zamorano Gómez JL, Galderisi M (eds) Anti-cancer treatments and cardiotoxicity. Academic Press, Boston, pp 7–11
Fried W, Kedo A, Barone J (1977) Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma. Cancer Res 37:1205–1209
Friedman OM, Seligman AM (1954) Preparation of N-phosphorylated derivatives of Bis-β-chloroethylamine1a. J Am Chem Soc 76:655–658
Galm U, Hager MH, Van Lanen SG, Ju J, Thorson JS, Shen B (2005) Antitumor antibiotics: bleomycin, enediynes, and mitomycin. Chem Rev 105:739–758
Galton DA (1953) Myleran in chronic myeloid leukaemia; results of treatment. Lancet (London, England) 264:208–213
Galton DA, Till M, Wiltshaw E (1958) Busulfan (1, 4-dimethanesulfonyloxybutane, myleran); summary of clinical results. Ann N Y Acad Sci 68:967–973
Ganai SA (2016a) Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies. J Chemother (Florence, Italy) 28:247–254
Ganai SA (2016b) Histone deacetylase inhibitor sulforaphane: the phytochemical with vibrant activity against prostate cancer. Biomed Pharmacother 81:250–257
Ganai SA (2016c) Panobinostat: the small molecule metalloenzyme inhibitor with marvelous anticancer activity. Curr Top Med Chem 16:427–434
Glynne-Jones R, Chau I (2013) Neoadjuvant therapy before surgical treatment. EJC Suppl 11:45–59
Goa KL, Faulds D (1994) Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 5:200–234
Goedhals L, Wiyk AL, Smith BL, Fourie S (2006) Pemetrexed (Alimta (R), LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer 16:1172–1178
Gore ME, Fryatt I, Wiltshaw E, Dawson T, Robinson BA, Calvert AH (1989) Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 60:767–769
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P, McGuire JR, Iglesias J (2012) Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer 12:313–321
Granados-Romero J, Valderrama-Treviño A, Contreras Flores E, Barrera-Mera B, Herrera M, Uriarte-Ruíz K, Ceballos-Villalva JC, Estrada A, Rodríguez C, Arauz-Peña G (2017) Colorectal cancer: a review. Int J Res Med Sci 5:4667
Grant J (2001) Man and medicine: a history.: Farokh Erach Udwadia. (518 pages, £31.50.) Oxford University Press, 2000. ISBN 0-19-565457-9. Fam Pract 18:649–650
Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC et al (1992) Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706–713
Groninger E, Meeuwsen-de Boar T, Koopmans P, Uges D, Sluiter W, Veerman A, Kamps W, de Graaf S (2002) Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res 52:113–118
Gueritte F (2001) General and recent aspects of the chemistry and structure-activity relationships of taxoids. Curr Pharm Des 7:1229–1249
Guimaraes I, Guimarães S, Daltoé R, Herlinger A, Klesia P, Madeira T, Ladislau I, Valadão P, Morais L, Junior S, Teixeira G, Amorim D, Zipinotti D, Santos K, Demuth L, Batista A, Rangel (2013) Conventional cancer treatment. https://doi.org/10.5772/55282
Haddow A, Timmis GM (1953) Myleran in chronic myeloid leukæmia chemical constitution and biological action. Lancet 261:207–208
Hagner N, Joerger M (2010) Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2:293–301
Hajdu SI (2011) A note from history: landmarks in history of cancer, part 1. Cancer 117:1097–1102
Haldar S, Chintapalli J, Croce CM (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253–1255
Hall EJ (2007) Cancer caused by x-rays--a random event? The lancet. Oncology 8:369–370
Hall MD, Hambley TW (2002) Platinum(IV) antitumour compounds: their bioinorganic chemistry. Coord Chem Rev 232:49–67
Hall AG, Tilby MJ (1992) Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 6:163–173
Han R, Yang YM, Dietrich J, Luebke A, Mayer-Proschel M, Noble M (2008) Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7:12
Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer (Oxford, England: 1990) 34:1514–1521
Harding M, Kennedy R, Mill L, MacLean A, Duncan I, Kennedy J, Soukop M, Kaye SB (1988) A pilot study of carboplatin (JM8, CBDCA) and chlorambucil in combination for advanced ovarian cancer. Br J Cancer 58:640–643
Hartwell JL, Schrecker AW (1951) Components of podophyllin. V. The constitution of podophyllotoxin1. J Am Chem Soc 73:2909–2916
Hassanpour SH, Dehghani M (2017) Review of cancer from perspective of molecular. J Cancer Res Pract 4:127–129
Hazarika M, White RM, Johnson JR, Pazdur R (2004) FDA drug approval summaries: pemetrexed (Alimta). Oncologist 9:482–488
Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP (1993) Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr:55–61
Hsiao Y-L, Chang P-C, Huang H-J, Kuo C-C, Chen CY-C (2014) Treatment of acute lymphoblastic leukemia from traditional Chinese medicine. Evid Based Complement Alternat Med 2014:601064–601064
Hui YF, Reitz J (1997) Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 54:162–170. quiz 197-168
Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461:1071–1078
Janke C, Magiera MM (2020) The tubulin code and its role in controlling microtubule properties and functions. Nat Rev Mol Cell Biol 21:307–326
Johnstone TC, Suntharalingam K, Lippard SJ (2016) The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 116:3436–3486
Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265
Jordan MA, Thrower D, Wilson L (1991) Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 51:2212–2222
Kacprzak KM (2013) Chemistry and biology of camptothecin and its derivatives. In: Ramawat KG, Mérillon J-M (eds) Natural products: phytochemistry, botany and metabolism of alkaloids, phenolics and terpenes. Springer, Berlin, pp 643–682
Kakde D, Jain D, Shrivastava V, Kakde R, Patil AT (2011) Cancer therapeutics—opportunities, challenges and advances in drug delivery. J Appl Pharm Sci 1:1–10
Kane BJ, Kuhn JG, Roush MK (1992) Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Ann Pharmacother 26:939–947
Karahalil B, Yardım-Akaydin S, Baytas S (2019) An overview of microtubule targeting agents for cancer therapy. Arch Ind Hyg Toxicol 70:160–172
Karasawa T, Steyger PS (2015) An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett 237:219–227
Kartner N, Riordan JR, Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science (New York, N.Y.) 221:1285–1288
Kim EH, Andriole GL (2018) Prostate cancer review. Mo Med 115:131–131
Kim KI, Huh IS, Kim IW, Park T, Ahn KS, Yoon SS, Yoon JH, Oh JM (2013) Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. Eur J Cancer (Oxford, England: 1990) 49:403–410
Kingston DGI (2009) Tubulin-interactive natural products as anticancer agents. J Nat Prod 72:507–515
Klohs WD, Kraker AJ (1992) Pentostatin: future directions. Pharmacol Rev 44:459–477
Koutinos G, Stathopoulos GP, Dontas I, Perrea-Kotsarelis D, Couris E, Karayannacos PE, Deliconstantinos G (2002) The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study. Anticancer Res 22:815–820
Kripp M, Hofheinz R-D (2008) Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine. Int J Nanomed 3:397–401
Krouwer D, McDermott M, Prados M (1990) Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas. J Neuro-Oncol 8:189–191
Kuppers R, Hansmann ML (2005) The Hodgkin and Reed/Sternberg cell. Int J Biochem Cell Biol 37:511–517
Lansiaux A (2011) Antimetabolites. Bull Cancer 98:1263–1274
Lee J-I (2005) Systemic overview of 5-FU based chemotherapy in stomach cancer. Korean J Clin Oncol 1:82–91
Lefkowitz IB, Packer RJ, Siegel KR, Sutton LN, Schut L, Evans AE (1990) Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. Cancer 65:412–417
Lemoine A, Lucas C, Ings RMJ (1991) Metabolism of the chloroethylnitrosoureas. Xenobiotica 21:775–791
Li F, Jiang T, Li Q, Ling X (2017) Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Am J Cancer Res 7:2350–2394
Links M, Brown R (1999) Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Mol Med 1999:1–21
Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP (2000) Mechanism of action of camptothecin. Ann N Y Acad Sci 922:1–10
Loehrer PJ Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540–546
Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338
Lucas DM, Still PC, Pérez LB, Grever MR, Kinghorn AD (2010) Potential of plant-derived natural products in the treatment of leukemia and lymphoma. Curr Drug Targets 11:812–822
Ludwig T, Riethmüller C, Gekle M, Schwerdt G, Oberleithner H (2004) Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 66:196–202
Lv S, Li A, Wu H, Wang X (2019) Observation of clinical efficacy and toxic and side effects of pirarubicin combined with cytarabine on acute myeloid leukemia. Oncol Lett 17:3411–3417
Malavalli G, Karra S, Muniyappa B (2013) Teratocarcinoma in a non seminomatous, mixed germ cell tumour of the testis-a rare entity. J Clin Diagn Res 7:1439–1440
Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, Vecchis L (2007) Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56:275–287
Marinello J, Delcuratolo M, Capranico G (2018) Anthracyclines as topoisomerase II poisons: from early studies to new perspectives. Int J Mol Sci 19:3480
Martin M (2006) Clinical experience with pemetrexed in breast cancer. Semin Oncol 33:S15–S18
Martino E, Casamassima G, Castiglione S, Cellupica E, Pantalone S, Papagni F, Rui M, Siciliano AM, Collina S (2018) Vinca alkaloids and analogues as anti-cancer agents: looking back, peering ahead. Bioorg Med Chem Lett 28:2816–2826
Meegan MJ, O’Boyle NM (2019) Special issue “anticancer drugs”. Pharmaceuticals (Basel) 12:134
Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, Dunnenberger HM, Marsh S, McLeod HL, Giacomini K, Becker ML, Gaedigk R, Leeder JS, Kager L, Relling MV, Evans W, Klein TE, Altman RB (2011) PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 21:679–686
Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, Sasaki I (2010) 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers 2:1717–1730
More GS, Thomas AB, Chitlange SS, Nanda RK, Gajbhiye RL (2019) Nitrogen mustards as alkylating agents: a review on chemistry, mechanism of action and current USFDA status of drugs. Anti Cancer Agents Med Chem 19:1080–1102
Morrison BA (2003) Soft tissue sarcomas of the extremities. Proc (Bayl Univ Med Cent) 16:285–290
Moudi M, Go R, Yien CYS, Nazre M (2013) Vinca alkaloids. Int J Prev Med 4:1231–1235
Mukhtar E, Adhami VM, Mukhtar H (2014) Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther 13:275–284
Nagai H, Kim YH (2017) Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis 9:448–451
Nenot JC, Stather JW (1979) Chapter 6 - Pathological effects in animals. In: Nenot JC, Stather JW (eds) The toxicity of plutonium, americium and curium. Pergamon, pp 103–141
Neville BW, Damm DD, Allen CM, Chi AC (2019) 10 - Epithelial pathology. In: Neville BW, Damm DD, Allen CM, Chi AC (eds) Color atlas of oral and maxillofacial diseases. Elsevier, Philadelphia, pp 223–271
Newton HB (2006) Chapter 2 - Clinical pharmacology of brain tumor chemotherapy. In: Newton HB (ed) Handbook of brain tumor chemotherapy. Academic Press, San Diego, pp 21–43
Neyns B, Tosoni A, Hwu WJ, Reardon DA (2010) Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer 116:2868–2877
Nicolle A, Proctor SJ, Summerfield GP (2004) High dose chlorambucil in the treatment of lymphoid malignancies. Leuk Lymphoma 45:271–275
Ogura M (2003) [Cladribine]. Gan to kagaku ryoho. Cancer Chemother 30:309–317
Ojima I, Lichtenthal B, Lee S, Wang C, Wang X (2016) Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat 26:1–20
Ormrod D, Spencer CM (1999) Topotecan: a review of its efficacy in small cell lung cancer. Drugs 58:533–551
Osborn MJ, Freeman M, Huennekens FM (1958) Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc Soc Exp Biol Med 97:429–431
Pacheco DY, Stratton NK, Gibson NW (1989) Comparison of the mechanism of action of busulfan with hepsulfam, a new antileukemic agent, in the L1210 cell line. Cancer Res 49:5108–5110
Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302
Pasquier E, Kavallaris M (2008) Microtubules: a dynamic target in cancer therapy. IUBMB Life 60:165–170
Peters G (2014) Novel developments in the use of antimetabolites. Nucleosides Nucleotides Nucleic Acids 33:358–374
Piller GJ (2001) Leukaemia – a brief historical review from ancient times to 1950. Br J Haematol 112:282–292
Plunkett W, Huang P, Gandhi V (1990) Metabolism and action of fludarabine phosphate. Semin Oncol 17:3–17
Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789–802
Portlock CS, Fischer DS, Cadman E, Lundberg WB, Levy A, Bobrow S, Bertino JR, Farber L (1987) High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin’s lymphoma. Cancer Treat Rep 71:1029–1031
Pratt CB, Douglass EC, Etcubanas E, Goren MP, Green AA, Hayes FA, Horowitz ME, Meyer WH, Thompson EI, Wilimas JA (1989) Clinical studies of ifosfamide/mesna at St Jude Children’s Research Hospital, 1983–1988. Semin Oncol 16:51–55
Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17
Ralhan R, Kaur J (2007) Alkylating agents and cancer therapy. Expert Opin Ther Pat 17:1061–1075
Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053–1071
Read WL, Mortimer JE, Picus J (2002) Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94:847–853
Rivkin SE, Green S, Metch B, Glucksberg H, Gad-el-Mawla N, Constanzi JJ, Hoogstraten B, Athens J, Maloney T, Osborne CK et al (1989) Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study. J Clin Oncol 7:1229–1238
Robak T, Korycka A, Lech-Maranda E, Robak P (2009) Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules (Basel, Switzerland) 14:1183–1226
Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15
Rundles RW, Grizzle J, Bell WN, Corley CC, Frommeyer WB, Greenberg BG, Huguley CM, Watson James G, Jones R, Larsen WE, Loeb V, Leone LA, Palmer JG, Riser WH, Wilson SJ (1959) Comparison of chlorambucil and Myleran® in chronic lymphocytic and granulocytic leukemia. Am J Med 27:424–432
Saeidnia S (2015) Anticancer antibiotics. In: Saeidnia S (ed) New approaches to natural anticancer drugs. Springer, Cham, pp 51–66
Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100–1104
Saris CP, van de Vaart PJ, Rietbroek RC, Blommaert FA (1996) In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17:2763–2769
Schabel FM Jr, Johnston TP, Mc CG, Montgomery JA, Laster WR, Skipper HE (1963) Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. Cancer Res 23:725–733
Schwarzerová K, Bellinvia E, Martinek J, Sikorová L, Dostál V, Libusová L, Bokvaj P, Fischer L, Schmit AC, Nick P (2019) Tubulin is actively exported from the nucleus through the Exportin1/CRM1 pathway. Sci Rep 9:5725
Shaikh AY, Suryadevara S, Tripathi A, Ahmed M, Kane JL, Escobar J, Cerny J, Nath R, McManus DD, Shih J, McGuiness ME, Tighe DA, Meyer TE, Ramanathan M, Aurigemma GP (2016) Mitoxantrone-induced cardiotoxicity in acute myeloid leukemia-a velocity vector imaging analysis. Echocardiography (Mount Kisco, N.Y.) 33:1166–1177
Shewach DS, Kuchta RD (2009) Introduction to cancer chemotherapeutics. Chem Rev 109:2859–2861
Siddik ZH (2005) Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. In: Alison MR (ed) The cancer handbook. https://doi.org/10.1002/0470025077.chap84b
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30
Smorenburg CH, Sparreboom A, Bontenbal M, Verweij J (2001) Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer (Oxford, England: 1990) 37:2310–2323
Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E (2001) The binding conformation of taxol in β-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci 98:5312–5316
Springer CJ, Antoniw P, Bagshawe KD, Searle F, Bisset GM, Jarman M (1990) Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem 33:677–681
Sreerama L (2014) Alkylating agents. In: Schwab M (ed) Encyclopedia of cancer. Springer, Berlin, pp 1–6
Stanczyk M, Sliwinski T, Trelinska J, Cuchra M, Markiewicz L, Dziki L, Bieniek A, Bielecka-Kowalska A, Kowalski M, Pastorczak A, Szemraj J, Mlynarski W, Majsterek I (2012) Role of base-excision repair in the treatment of childhood acute lymphoblastic leukaemia with 6-mercaptopurine and high doses of methotrexate. Mutat Res 741:13–21
Stentoft J (1990) The toxicity of cytarabine. Drug Saf 5:7–27
Stewart T, Pavlakis N, Ward M (2010) Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 40:303–307
Sun H, Huang K, Tang F, Li X, Wang X, Long S, Zhou S, Suolangquzhen, Zhang J, Ning R, Li S, Wang S, Ma D (2018) Adjuvant chemotherapy after surgery can improve clinical outcomes for patients with IB2-IIB cervical cancer with neoadjuvant chemotherapy followed by radical surgery. Sci Rep 8:6443–6443
Szucs Z, Jones RL (2016) Chapter 2 - Introduction to systemic antineoplastic treatments for cardiologists. In: Herrmann J (ed) Clinical cardio-oncology. Elsevier, pp 15–38
Tagliamento M, Genova C, Rossi G, Coco S, Rijavec E, Dal Bello MG, Boccardo S, Grossi F, Alama A (2019) Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. Expert Opin Investig Drugs 28:513–523
Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21:440–446
Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F (2005) Role of gemcitabine in cancer therapy. Future Oncol 1:7–17
Tounekti O, Kenani A, Foray N, Orlowski S, Mir LM (2001) The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. Br J Cancer 84:1272–1279
Valachis A, Mauri D, Polyzos NP, Mavroudis D, Georgoulias V, Casazza G (2010) Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol 73:220–227
van Maanen JM, Retel J, de Vries J, Pinedo HM (1988) Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 80:1526–1533
Verheij M (2008) Clinical biomarkers and imaging for radiotherapy-induced cell death. Cancer Metastasis Rev 27:471–480
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644
Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–343
Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27:23–44
Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888–3890
Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327
Wiltshaw E (1965) Chlorambucil in the treatment of primary adenocarcinoma of the ovary. J Obstet Gynaecol Br Commonw 72:586–594
Wong A, Soo R, Yong W-P, Innocenti F (2009) Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 41:77–88
Wosikowski K, Biedermann E, Rattel B, Breiter N, Jank P, Löser R, Jansen G, Peters GJ (2003) In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human Cancer cells 5. Clin Cancer Res 9:1917–1926
Yabar CS, Winter JM (2016) Pancreatic cancer: a review. Gastroenterol Clin N Am 45:429–445
Yang SW, Huang P, Plunkett W, Becker FF, Chan JY (1992) Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 267:2345–2349
Yoneda KY, Cross CE (2010) The pulmonary toxicity of anticancer agents. In: McQueen CA (ed) Comprehensive toxicology, 2nd edn. Elsevier, Oxford, pp 477–510
Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021–1027
Zhang N, Yin Y, Xu S-J, Chen W-S (2008) 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13:1551–1569
Zhang DS, Jin Y, Luo HY, Wang ZQ, Qiu MZ, Wang FH, Li YH, Xu RH (2015) Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study. Br J Cancer 112:266–270
Zhang F, Zhang Y, Jia Z, Wu H, Gu K (2019) Oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer: a meta-analysis. J Cancer 10:1923–1929
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ganai, S.A. (2020). Compendium of Mechanistic Insights of Distinct Conventional Anticancer Therapies and Their Grievous Toxicities. In: Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-15-8179-3_6
Download citation
DOI: https://doi.org/10.1007/978-981-15-8179-3_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-8178-6
Online ISBN: 978-981-15-8179-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)